Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Where does sevabertinib fit in HER2-mutant NSCLC?
The toolkit now includes sevabertinib, zongertinib, and trastuzumab deruxtecan.
More options are good news. But sequencing, toxicity, CNS activity, and cross-trial caveats still matter.”
____ ____ ____
Gilberto Lopes was recognized among OncoDaily’s ‘Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024’, highlighting his contributions to the field of oncology.
Nominations for ‘100 Influential People in Oncology 2026’ are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit Your Nomination by September 15.
